Retrospective WGS Study

The Wellcome Sanger Institute

Status: Invitation-only

Conditions: Neoplasm; Pediatric Cancer; Cancer

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT06820294

319310

Details and patient eligibility

About

This retrospective case series reviews clinical notes to assess whether NHS whole genome sequencing provides tangible benefits for paediatric tumours.

Full description

The NHSE-commissioned whole genome sequencing programme went live at the end of 2020. It remains as yet unproven, whether this whole genome sequencing programme for children with cancer can deliver tangible benefits in real-time. There is an urgent need, therefore, to assess whether children with tumours who are receiving NHS whole genome sequencing are actually benefiting from this additional assay. This is a retrospective case series. The principal methodology is that of reviewing clinical notes to assess whether children with tumours have benefited from NHSE whole genome sequencing. Apart from the contribution of our work to the scientific literature, this research will inform government on the potential benefits, or lack thereof, of the live NHSE whole genome programme and has the potential to influence policy on whether this programme should be continued.

Enrollment: 2,000 estimated patients

Sex: All

Ages: Under 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing.

Exclusion criteria

• Anyone not offered NHSE whole genome sequencing
• Individuals beyond the age of 21
• Individuals without a neoplastic disorder.

Trial design

2,000 participants in 1 patient group

All children/young people (up to 21years) diagnosed with neoplastic disorder who have had NHSE WGS

Description:

All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing.

Treatment:

Other: No intervention